Study of HAIC with Lenvatinib and PD-1 Inhibitor Treatment for Infiltrative Liver Cancer

What this Trial Is About

Researchers are studying advanced infiltrative hepatocellular carcinoma HCC, a type of liver cancer, by evaluating the combined use of hepatic arterial infusion chemotherapy HAIC, lenvatinib, and PD-1 inhibitors. This observational real-world study aims to assess how effective and safe this combination is compared to lenvatinib alone. The study will gather clinical data to better understand treatment outcomes for this specific patient group. The study involves two groups one receiving HAIC combined with lenvatinib and a PD-1 inhibitor, and the other receiving only lenvatinib. HAIC is given using a FOLFOX chemotherapy regimen through a specialized infusion procedure, while lenvatinib is taken orally once daily based on body weight. PD-1 inhibitors like tislelizumab, toripalimab, sintilimab, or camrelizumab are given intravenously every three weeks. Participants receive these treatments as part of their standard care. Participants will be monitored and assessed regularly through imaging tests such as MRI or CT scans to confirm their diagnosis and evaluate tumor characteristics. Researchers will track overall survival over 24 months and progression-free survival over 12 months. Patient safety and treatment effects will be recorded, and follow-up will continue until the study ends. The total participation duration varies depending on individual treatment and outcomes.

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma